TY - JOUR
T1 - From genome to antivirals
T2 - SARS as a test tube
AU - Kliger, Yossef
AU - Levanon, Erez Y.
AU - Gerber, Doron
PY - 2005/3/1
Y1 - 2005/3/1
N2 - The severe acute respiratory syndrome (SARS) epidemic brought into the spotlight the need for rapid development of effective anti-viral drugs against newly emerging viruses. Researchers have leveraged the 20-year battle against AIDS into a variety of possible treatments for SARS. Most prominently, based solely on viral genome information, silencers of viral genes, viral-enzyme blockers and viral-entry inhibitors were suggested as potential therapeutic agents for SARS. In particular, inhibitors of viral entry, comprising therapeutic peptides, were based on the recently launched anti-HIV drug enfuvirtide. This could represent one of the most direct routes from genome sequencing to the discovery of antiviral drugs.
AB - The severe acute respiratory syndrome (SARS) epidemic brought into the spotlight the need for rapid development of effective anti-viral drugs against newly emerging viruses. Researchers have leveraged the 20-year battle against AIDS into a variety of possible treatments for SARS. Most prominently, based solely on viral genome information, silencers of viral genes, viral-enzyme blockers and viral-entry inhibitors were suggested as potential therapeutic agents for SARS. In particular, inhibitors of viral entry, comprising therapeutic peptides, were based on the recently launched anti-HIV drug enfuvirtide. This could represent one of the most direct routes from genome sequencing to the discovery of antiviral drugs.
UR - http://www.scopus.com/inward/record.url?scp=14644406266&partnerID=8YFLogxK
U2 - 10.1016/S1359-6446(04)03320-3
DO - 10.1016/S1359-6446(04)03320-3
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 15749283
AN - SCOPUS:14644406266
SN - 1359-6446
VL - 10
SP - 345
EP - 352
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 5
ER -
